THE 3HP-OPTIONS TRIAL
Study period: August 2019 – Ongoing.
The study focuses on Options for Delivering Isoniazid-Rifapentine (3HP) to people living with HIV for TB Prevention. The Study is conducted at Mulago ISS (AIDS) Clinic in Kampala with a target population of 1656 adults living with the HIV infection.
Objectives:
To compare the uptake of 3HP under three delivery strategies:
- Facilitated Directly Observed Therapy
- Facilitated Self-Administered Therapy, and
- Informed patient choice (using a decision aid) between facilitated Directly Observed Therapy and facilitated Self-Administered Therapy.
